Cantor Fitzgerald Reiterates Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report issued on Tuesday,Benzinga reports. They presently have a $170.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 43.01% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. UBS Group began coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target for the company. Wedbush restated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. TD Cowen dropped their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average price target of $191.57.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded down $0.62 on Tuesday, reaching $118.88. The stock had a trading volume of 47,049 shares, compared to its average volume of 422,381. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The business’s 50-day moving average price is $132.32 and its two-hundred day moving average price is $132.36. The stock has a market cap of $7.21 billion, a P/E ratio of -14.72 and a beta of 0.64.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently bought and sold shares of ASND. Groupama Asset Managment acquired a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $60,000. Janus Henderson Group PLC grew its position in shares of Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after buying an additional 267,881 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares during the period. Finally, Frazier Life Sciences Management L.P. bought a new position in Ascendis Pharma A/S during the 3rd quarter worth approximately $19,908,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.